Hepion COO builds 5.7% stake via $150K buy

Hepion Pharmaceuticals, Inc. (HEPA) had a Schedule 13D filed by director and Chief Operating Officer Sireesh Appajosyula, reporting beneficial ownership of 5,250,000 shares of common stock, including 2,000,000 shares issuable upon exercise of warrants.

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. (HEPA) had a Schedule 13D filed by director and Chief Operating Officer Sireesh Appajosyula, reporting beneficial ownership of 5,250,000 shares of common stock, including 2,000,000 shares issuable upon exercise of warrants. This represents 5.7% of Hepion’s common stock, based on 90,219,317 shares outstanding as of August 10, 2026.

The filing states an aggregate purchase price of approximately $150,000 for the securities. On April 21, 2026 he acquired 1,250,000 shares for $50,000, and on July 31, 2026 he acquired 2,000,000 shares plus a warrant for 2,000,000 shares for $100,000. The warrant is immediately exercisable at $0.06 per share, subject to a Beneficial Ownership Limitation. The stake is described as acquired for investment purposes, with no additional specific corporate plans disclosed.

Key Figures

Beneficial ownership: 5,250,000 shares Percent of class: 5.7% Shares outstanding: 90,219,317 shares +5 more

8 metrics

Beneficial ownership 5,250,000 shares Total shares beneficially owned by Sireesh Appajosyula, including warrant shares

Percent of class 5.7% Percentage of Hepion common stock represented by 5,250,000 shares

Shares outstanding 90,219,317 shares Hepion common stock outstanding as of August 10, 2026

Aggregate purchase price $150,000.00 Total purchase price for shares of common stock beneficially owned

April 21, 2026 purchase 1,250,000 shares for $50,000 Common stock acquired under Securities Purchase Agreement dated April 21, 2026

July 31, 2026 equity purchase 2,000,000 shares for $100,000 Common stock acquired under Securities Purchase Agreement dated July 31, 2026

Warrant exercise price $0.06 per share Exercise price of warrant to purchase 2,000,000 shares of common stock

Warrant shares 2,000,000 shares Number of Hepion common shares underlying the warrant held by the reporting person

Key Terms

Beneficial Ownership Limitation, Securities Purchase Agreement, sole voting power, sole dispositive power

4 terms

Beneficial Ownership Limitation financial

"The warrant is immediately exercisable at $0.06 per share, subject to the Beneficial Ownership Limitation"

A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

Securities Purchase Agreement financial

"acquired 1,250,000 shares of Common Stock ... pursuant to a Securities Purchase Agreement"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

sole voting power financial

"Number of Shares Beneficially Owned by Each Reporting Person With: | 7 | Sole Voting Power"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Number of Shares Beneficially Owned by Each Reporting Person With: ... 9 | Sole Dispositive Power"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

What percentage of Hepion Pharmaceuticals (HEPA) does Sireesh Appajosyula report owning in this Schedule 13D?

The Schedule 13D reports that Sireesh Appajosyula beneficially owns 5.7% of Hepion Pharmaceuticals’ common stock, based on 90,219,317 shares outstanding as of August 10, 2026. This percentage includes shares underlying warrants that are currently exercisable.

How many Hepion (HEPA) shares does Sireesh Appajosyula beneficially own and how is this composed?

He beneficially owns 5,250,000 shares of Hepion common stock, including 2,000,000 shares issuable upon exercise of a warrant. He reports 5,250,000 shares of both sole voting power and sole dispositive power, with no shared voting or dispositive power.

What transactions did Sireesh Appajosyula make in Hepion (HEPA) stock in 2026?

On April 21, 2026, he acquired 1,250,000 shares for $50,000 under a Securities Purchase Agreement. On July 31, 2026, he acquired 2,000,000 shares and a warrant for 2,000,000 shares for $100,000, also under a Securities Purchase Agreement.

What is the exercise price and key feature of the warrant held by Sireesh Appajosyula in Hepion (HEPA)?

The warrant held by Sireesh Appajosyula is immediately exercisable at an exercise price of $0.06 per share for 2,000,000 shares of Hepion common stock. Its exercise is subject to a Beneficial Ownership Limitation contained in the warrant terms.

What is the stated purpose of Sireesh Appajosyula’s investment in Hepion (HEPA) according to the Schedule 13D?

The filing states that the common stock was acquired for investment purposes. It also notes that he may make further acquisitions of Hepion common stock from time to time, and that he has no additional specific plans or proposals of the types listed under Item 4.

What is Sireesh Appajosyula’s role at Hepion Pharmaceuticals (HEPA)?

Sireesh Appajosyula is identified as a director and Chief Operating Officer of Hepion Pharmaceuticals, Inc. His business address is listed at the company’s Red Bank, New Jersey office.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/20/2026 - 04:30 PM Accepted by SEC EDGAR 08/20/2026 - 04:30 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

Hepion Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

426897401

(CUSIP Number)

Sireesh Appajosyula
c/o Hepion Pharmaceuticals, inc., 34 Shrewsbury Ave., Suite 1D
Red Bank, NJ, 07701
(732) 902-4000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/03/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 426897401

1

Name of reporting person

Sireesh Appajosyula

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 5,250,000.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 5,250,000.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

5,250,000.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.7 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

(1) The percentage reported in row 13 above is calculated with a numerator of 5,250,000 shares beneficially owned by the reporting person including 2,000,000 shares of common stock issuable upon exercise of warrants and a denominator of 90,219,317 shares of Common Stock outstanding as of August 10, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: Hepion Pharmaceuticals, Inc.
(c)	Address of Issuer's Principal Executive Offices: c/o Hepion Pharmaceuticals, inc., 34 Shrewsbury Ave., Suite 1D, Red Bank, NEW JERSEY , 07701.
Item 2.	Identity and Background
(a)	This Statement is being filed on behalf of Sireesh Appajosyula (the "Reporting Person").
(b)	The business address of the Reporting Person is 34 Shrewsbury Ave, Red Bank, NJ 07701.
(c)	Mr. Appajosyula is a director and Chief Operating Officer of the Issuer.
(d)	No
(e)	No
(f)	Mr. Appajosyula is a citizen of the United States of America.
Item 3.	Source and Amount of Funds or Other Consideration
	The aggregate purchase price of the shares of Common Stock beneficially owned by the Reporting Person was approximately $150,000.00. On April 21, 2026 the Reporting Person acquired 1,250,000 shares of Common Stock of the Issuer pursuant to a Securities Purchase Agreement dated April 21, 2026 for an aggregate purchase price of $50,000. On July 31, 2026, the Reporting Person acquired 2,000,000 shares of Common Stock of the Issuer and one warrant to purchase 2,000,000 shares of Common Stock of the Issuer pursuant to a Securities Purchase Agreement dated July 31, 2026 for an aggregate purchase price of $100,000. The warrant is immediately exercisable at $0.06 per share, subject to the Beneficial Ownership Limitation contained therein.
Item 4.	Purpose of Transaction
	The Common Stock owned by the Reporting Person was acquired for investment purposes. The Reporting Person may make further acquisitions of the Common Stock from time to time. Except for the foregoing, the Reporting Person has no plans or proposals which relate to, or could result in, any of the matters referred to in Item 4 of Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	See response to Item 5(a) on the cover page for the Reporting Person.
(b)	See responses to Item 5(b) on the cover page for the Reporting Person.
(c)	On July 31, 2026, the Reporting Person acquired 2,000,000 shares of Common Stock of the Issuer and one warrant to purchase 2,000,000 shares of Common Stock of the Issuer pursuant to a Securities Purchase Agreement dated July 31, 2026 for an aggregate purchase price of $100,000. Except as described above, the Reporting Person has not effected any transaction in the Common Stock during the past sixty days.
(d)	No person other than the Reporting Person is known to have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, the securities reported herein.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Other than as described herein, the Reporting Person does not have any contracts, arrangements, understandings or relationships with respect to the securities of the Issuer.
Item 7.	Material to be Filed as Exhibits.
	None

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sireesh Appajosyula

Signature:	/s/ Sireesh Appajosyula
Name/Title:	Sireesh Appajosyula
Date:	08/20/2026